Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis

被引:213
|
作者
Comabella, Manuel [1 ]
Fernandez, Marta [1 ]
Martin, Roland [2 ]
Rivera-Vallve, Stephanie [3 ]
Borras, Eva [3 ]
Chiva, Cristina [3 ]
Julia, Eva [1 ]
Rovira, Alex [4 ]
Canto, Ester [1 ]
Carlos Alvarez-Cermeno, Jose [5 ,6 ]
Maria Villar, Luisa [5 ,6 ]
Tintore, Mar [1 ]
Montalban, Xavier [1 ]
机构
[1] Hosp Univ Vall Hebron, Unitat Neuroimmunol Clin, Ctr Esclerosi Multiple Catalunya, CEM Cat, Barcelona 08035, Spain
[2] Univ Med Ctr Eppendorf, Ctr Mol Neurobiol Hamburg ZMNH, Inst Neuroimmunol & Clin MULTIPLE SCLEROSIS Res, Hamburg, Germany
[3] Univ Pompeu Fabra, Serv Prote, Barcelona, Spain
[4] Hosp Univ Vall Hebron, Magnet Resonance Unit IDI, Barcelona 08035, Spain
[5] Hosp Ramon & Cajal, Dept Neurol, E-28034 Madrid, Spain
[6] Hosp Ramon & Cajal, Dept Immunol, E-28034 Madrid, Spain
关键词
clinically isolated syndrome; multiple sclerosis; proteomics; chitinase; 3-like; 1; cerebrospinal fluid; HUMAN CARTILAGE GLYCOPROTEIN-39; CSF PROTEOME ANALYSIS; SERUM YKL-40; ANTIMYELIN ANTIBODIES; RHEUMATOID-ARTHRITIS; DIAGNOSTIC-CRITERIA; MRI; MARKER; CHITOTRIOSIDASE; DISABILITY;
D O I
10.1093/brain/awq035
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
In most patients with multiple sclerosis, the disease initiates with a first attack or clinically isolated syndrome. At this phase, magnetic resonance imaging is an important predictor of conversion to multiple sclerosis. With the exception of oligoclonal bands, the role of other biomarkers in patients with clinically isolated syndrome is controversial. In the present study, we aimed to identify proteins associated with conversion to multiple sclerosis in patients with clinically isolated syndrome. We applied a mass spectrometry-based proteomic approach (isobaric labelling) to previously collected pooled cerebrospinal fluid samples from patients with clinically isolated syndrome, who subsequently converted to clinically definite multiple sclerosis (n = 30) and patients who remained as having clinically isolated syndrome (n = 30). Next, three of the most represented differentially expressed proteins, i.e. ceruloplasmin, vitamin D-binding protein and chitinase 3-like 1 were selected for validation in individual cerebrospinal fluid samples by enzyme-linked immunosorbent assay. Only chitinase 3-like 1 was validated and cerebrospinal fluid levels were increased in patients who converted to clinically definite multiple sclerosis compared with patients who continued as clinically isolated syndrome (P = 0.00002) and controls (P = 0.012). High cerebrospinal fluid levels of chitinase 3-like 1 significantly correlated with the number of gadolinium enhancing lesions and the number of T2 lesions observed in brain magnetic resonance imaging scans performed at baseline, and were associated with disability progression during follow-up and shorter time to clinically definite multiple sclerosis (log-rank P-value = 0.003). Cerebrospinal fluid chitinase 3-like 1 levels were also measured in a second validation clinically isolated syndrome cohort and found to be increased in patients who converted to multiple sclerosis compared with patients who remained as having clinically isolated syndrome (P = 0.018). Our results indicate that patients who will convert to clinically definite multiple sclerosis could be distinguished from those patients who will remain as clinically isolated syndrome by proteomic analysis of cerebrospinal fluid samples. Although protein levels are also increased in other disorders characterized by chronic inflammation, chitinase 3-like 1 may serve as a prognostic biomarker for conversion to multiple sclerosis and development of disability which may help to improve the understanding of the aetiopathogenesis in the early stages of multiple sclerosis.
引用
收藏
页码:1082 / 1093
页数:12
相关论文
共 50 条
  • [1] Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases
    Kusnierova, Pavlina
    Zeman, David
    Hradilek, Pavel
    Zapletalova, Olga
    Stejskal, David
    [J]. PLOS ONE, 2020, 15 (05):
  • [2] Cognitive impairment in early stages of multiple sclerosis is associated with high cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain
    Quintana, E.
    Coll, C.
    Salavedra-Pont, J.
    Munoz-San Martin, M.
    Robles-Cedeno, R.
    Tomas-Roig, J.
    Buxo, M.
    Matute-Blanch, C.
    Villar, L. M.
    Montalban, X.
    Comabella, M.
    Perkal, H.
    Gich, J.
    Ramio-Torrenta, L.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 (09) : 1189 - 1191
  • [3] Plasma chitinase 3-like 1 levels in patients with multiple sclerosis
    Canto, E.
    Vidal-Jordana, A.
    Malhotra, S.
    Rio, J.
    Tintore, M.
    Montalban, X.
    Comabella, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S268 - S268
  • [4] Cerebrospinal fluid chitinase 3-like 1 levels in patients with radiologically isolated syndromes
    Matute-Blanch, C.
    Villar, L. M.
    Evdoshenko, E.
    Makshakov, G.
    Nazarov, V.
    Lapin, S.
    Midaglia, L.
    Vidal-Jordana, A.
    Drulovic, J.
    Garcia-Merino, A.
    Saiz, A.
    Zettl, U. K.
    Schroeder, I.
    Ramio-Torrenta, L.
    Quintana, E.
    Galimberti, D.
    Montalban, X.
    Comabella, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 587 - 588
  • [5] Validation of cerebrospinal fluid chitinase 3-like 1 as a prognostic biomarker of conversion to multiple sclerosis and disease severity in patients with clinically isolated syndromes
    Canto, E.
    Tintore, M.
    Costa, C.
    Arrambide, G.
    Villar, L. M.
    Alvarez-Cermeno, J. C.
    Deisenhammer, F.
    Hegen, H.
    Khademi, M.
    Olsson, T.
    Piehl, F.
    Bartos, A.
    Simova, D.
    Kotoucova, J.
    Kuhle, J.
    Kappos, L.
    Garcia-Merino, J. A.
    Saiz, A.
    Blanco, Y.
    Hintzen, R.
    Jafari, N.
    Brassat, D.
    Tumani, H.
    Lauda, F.
    Roesler, R.
    Rejdak, K.
    Papuc, E.
    de Andres, C.
    Khalil, M.
    Galimberti, D.
    Scarpini, E.
    Montalban, X.
    Comabella, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 44 - 45
  • [6] Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis
    Modvig, S.
    Degn, M.
    Roed, H.
    Sorensen, T. L.
    Larsson, H. B. W.
    Langkilde, A. R.
    Frederiksen, J. L.
    Sellebjerg, F.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 (14) : 1761 - 1770
  • [7] Serum chitinase 3-like 1 levels in patients with multiple sclerosis and neuromyelitis optica
    Kaya, D.
    Altun, Z.
    Idiman, E.
    Karabay, N.
    Arslan, D.
    Kuzu, Z.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 154 - 154
  • [8] Chitinase 3-like 1 as potential therapeutic target in multiple sclerosis
    Matute-Blanch, C.
    Carballo-Carbaja, I.
    Navarro, L.
    Montalban, X.
    Comabella, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 403 - 404
  • [9] Chitinase 3-like 1 is not a target antigen in patients with multiple sclerosis
    Comabella, Manuel
    Deutschmann, Claudia
    Midaglia, Luciana
    Schierack, Peter
    Martinez, Julia
    Roggenbuck, Dirk
    Montalban, Xavier
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (09) : 1455 - 1457
  • [10] Chitinase 3-like 1 plasma levels are increased in patients with progressive forms of multiple sclerosis
    Canto, E.
    Reverter, F.
    Morcillo-Suarez, C.
    Matesanz, F.
    Fernandez, O.
    Izquierdo, G.
    Vandenbroeck, K.
    Rodriguez-Antigueedad, A.
    Urcelay, E.
    Arroyo, R.
    Otaegui, D.
    Olascoaga, J.
    Saiz, A.
    Navarro, A.
    Sanchez, A.
    Dominguez, C.
    Caminero, A.
    Horga, A.
    Tintore, M.
    Montalban, X.
    Comabella, M.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (07) : 983 - 990